Contract research organisation (CRO) QED Clinical Services has merged with fellow UK CRO QED Partnership, combining the two businesses under the QED Clinical Services umbrella.
The companies, which both operated out of Milton Keynes, were already long-term partners and the merger makes for “a highly complementary pairing”, QED Clinical Services said.
The enhanced QED Clinical Services organisation can draw on the “vast experience” of new senior managers such as Susan Ollier, former chair of the Institute of Clinical Research, and David Ollier, who has worked closely with the National Health Service (NHS), the new parent noted.
The QED Partnership team has a “wealth of experience” in research governance, auditing and training within the NHS, which will enable QED Clinical Services to expand significantly its non-commercial sponsor business, the latter added. The team also brings with it a diverse customer base, ranging from large pharmaceutical sponsors to small biotechnology companies.
QED Clinical Services provides Phase I-IV services in a number of therapeutic areas including oncology, central nervous system diseases, cardiology, immunology and metabolic disorders. It operates across multiple continents, with a presence in more than 25 countries worldwide and taking in emerging clinical trial markets such as Russia, India and China.
